HemoShear Therapeutics Appoints Head Of Research And Development
HemoShear Therapeutics announced the appointment of John E. Reardon, Ph.D. as Head of Research and Development. The full press release is available at the link below and at hemoshear.com/press-releases/Reardon.
“We are proud that John will lead our children’s rare metabolic disease programs to the clinic. John’s track record of leading programs from early discovery into the clinic in both virtual and large pharma R&D companies will be invaluable to our success.” – Jim Powers, CEO at HemoShear